Early Infant Micronutrition and Development

Recruiting Phase 2 Phase 3 Interventional Study
Vitamin B 12 Deficiency
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
1 Month – 2 Months
Sex
Any
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Treatment
Participants needed
600 (estimated)
Sponsor
Sykehuset Innlandet HF · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Globally, vitamin B12 deficiency is one of the most common micronutrient deficiencies. Poor status is also seen in affluent countries such as in Norway. Vitamin B12 is crucial for normal cell division and differentiation and necessary for the development and myelination of the central nervous system. Deficiency is also associated with impaired fetal and infant growth. In the proposed study we will…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Availability of informed verbal consent 2. Plan to reside in the defined study area for the next 12 months 3. Mothers intend to breastfeed their children for at least 8 months, and exclusively for 4 months Exclusion Criteria: 1. Severe systemic illness requiring hospitaliza…
Contacts

Carolien Konijnenberg, Ph.D

+47 61 28 74 94

carolien.konijnenberg@inn.no

CONTACT

Kjersti S Bakken, Ph.D.

+47 957 81 349

Kjersti.Sletten.Bakken@sykehuset-innlandet.no

CONTACT